Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00059-016-4427-3 http://scihub22266oqcxt.onion/10.1007/s00059-016-4427-3 C4839058!4839058!27071968     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Herz 2016 ; 41 (ä): 208-16 Nephropedia Template TP {{tp|p=27071968|t=2016. Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial |pdf=|usr=}}{{27071968}} gab.com Text Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial JO: Herz http://www.kidney.de/pget.php?&tw=1&pmid=27071968 #FOAvip Prevention of cardiovascular morbidity and mortality remains the key factor in the treatment of type 2 diabetes (T2DM). In the early phase of T2DM, multifactorial intervention is mandatory and glucose levels should be near normal, in particular in younger patients presenting with the highest cardiovascular risk. Anti-diabetic drugs without any risk for hypoglycaemia should be preferred in order to reduce clinical inertia and increase the long-term adherence to the treatment. In patients already presenting with cardiovascular disease, the best outcome may be expected with the triple oral therapy of metformin, pioglitazone, and empagliflozin, although a controlled prospective study versus insulin therapy is needed to confirm the expectation. Twit Text FOAVip Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial ????Herz http://www.kidney.de/pget.php?&tw=1&pmid=27071968 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27071968 #FOAvip English Wikipedia <ref>{{Cite pmid|27071968}}</ref> Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial #MMPMID27071968 Schernthaner G; Schernthaner GH Herz 2016[]; 41 (ä): 208-16 PMID27071968show ga Prevention of cardiovascular morbidity and mortality remains the key factor in the treatment of type 2 diabetes (T2DM). In the early phase of T2DM, multifactorial intervention is mandatory and glucose levels should be near normal, in particular in younger patients presenting with the highest cardiovascular risk. Anti-diabetic drugs without any risk for hypoglycaemia should be preferred in order to reduce clinical inertia and increase the long-term adherence to the treatment. In patients already presenting with cardiovascular disease, the best outcome may be expected with the triple oral therapy of metformin, pioglitazone, and empagliflozin, although a controlled prospective study versus insulin therapy is needed to confirm the expectation. äGlucose-lowering therapy in type 2 diabetes: New hope after the EMPA-R(epmc).pdf DeepDyve Pubget Overpricing